FDA
-
-
-
-
-
-
-
Ambrx Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX517 in mCRPC at ESMO Congress
-
-
-
-
-
-
-
ACE-Breast-02 Pivotal Phase 3 Study of Ambrx’s ARX788 for the Treatment of HER2 Positive Metastatic Breast Cancer Achieves Positive Results
-
-
-
-
-
-
-
Ambrx Biopharma Inc. Reports Full Year 2021 Financial Results; Provides Corporate Update
-
-
-
-
-
-
-
Anebulo Pharmaceuticals (ANEB) Names Biotechnology Industry Executive Simon Allen as CEO and Director
-
-
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

